Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
MesoCancerVac by Amphera for Malignant Mesothelioma: Likelihood of Approval
MesoCancerVac is under clinical development by Amphera and currently in Phase II for Malignant Mesothelioma. According to GlobalData, Phase II...